An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Cystic Fibrosis: Diagnosis and management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)
Top results in this bookTable of Contents
Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd Revised edition.
Cappellini MD, Cohen A, Eleftheriou A, et al.
Nicosia (CY): Thalassaemia International Federation; 2008.
Addressing Fetal Alcohol Spectrum Disorders (FASD).
Center for Substance Abuse Prevention (US).
Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2014. (Treatment Improvement Protocol (TIP) Series, No. 58.)
Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action; Martinez RM, Osei-Anto HA, McCormick M, editors.
Washington (DC): National Academies Press (US); 2020 Sep 10.
Sickle Cell Acute Painful Episode: Management of an Acute Painful Sickle Cell Episode in Hospital.
Manchester (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Jun. (NICE Clinical Guidelines, No. 143.)
WHO Guideline on Syphilis Screening and Treatment for Pregnant Women.
Geneva: World Health Organization; 2017.
Guideline: Optimal Serum and Red Blood Cell Folate Concentrations in Women of Reproductive Age for Prevention of Neural Tube Defects.
Geneva: World Health Organization; 2015.
Guideline: Delayed Umbilical Cord Clamping for Improved Maternal and Infant Health and Nutrition Outcomes.
Geneva: World Health Organization; 2014.
DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: Recommendations [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. (CADTH Optimal Use Report, No. 5.3d.)
Management of Indirect Neonatal Hyperbilirubinemia [Internet].
Sroufe NS, Vredeveld JL, Goodson SL, et al.
Ann Arbor (MI): Michigan Medicine University of Michigan; 2020 Jun.
ACMG ACT Sheets and Algorithms [Internet].
Bethesda (MD): American College of Medical Genetics and Genomics; 2001-.
CADTH Canadian Drug Expert Committee Recommendation: Cerliponase Alfa (Brineura — Biomarin Pharmaceutical [Canada] Inc.): Indication: For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May.
CADTH Canadian Drug Expert Committee Recommendation: Migalastat (Galafold — Amicus Therapeutics): Indication: Fabry Disease [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan.
CADTH Canadian Drug Expert Committee Recommendation: Nusinersen (Spinraza — Biogen Canada Inc.): Indication: Treatment of 5q spinal muscular atrophy. [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Mar.
Specialist neonatal respiratory care for babies born preterm.
London: National Institute for Health and Care Excellence (NICE); 2019 Apr 3. (NICE Guideline, No. 124.)
CADTH Canadian Drug Expert Committee Recommendation: Nitisinone (Nitisinone Tablets — Cycle Pharmaceuticals Ltd.): Indication: The treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.
CADTH Canadian Drug Expert Committee Recommendation: Sebelipase alfa (Kanuma — Alexion Pharmaceuticals, Inc.): Indication: Lysosomal acid lipase deficiency [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep 28.
CADTH Canadian Drug Expert Committee Recommendation: Nitisinone (Orfadin — Sobi Canada Inc.): Indication: The treatment of adult and pediatric patients with hereditary tyrosinemia type-1 in combination with a dietary restriction of tyrosine and phenylalanine [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb.
CADTH Canadian Drug Expert Committee Recommendation: Eliglustat (Cerdelga — Sanofi Genzyme): Indication: Type 1 Gaucher disease [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jul.
CADTH Canadian Drug Expert Committee Recommendation: Nitisinone (MDK-Nitisinone — MendeliKABs Inc.): Indication: The treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Apr.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on